Kynurenine Concentrations During Pregnancy in Women With or Without Chronic Kidney Disease - A Prospective Multicenter Study

NCT07411937 | Not Yet Recruiting

• 1 other identifier: PR26006
• Study Type: interventional
• Target: 204
• Locations: 1 country
• Sites: 1

Brief Summary

Chronic kidney disease (CKD) affects more than 10% of the population worldwide and represents the second most important risk factor for preeclampsia, a life-threatening complication of pregnancy responsible for approximately 80,000 maternal and 500,000 perinatal deaths each year. Experimental studies have suggested a causal link between CKD, relative kynurenine deficiency during pregnancy, and preeclampsia development. Kynurenine, a tryptophan metabolite, plays a central role at the materno-fetal interface, supporting placental energy production, maternal-fetal immune tolerance, and placental perfusion. This study will prospectively assess and compare longitudinal kynurenine concentrations in pregnant women with and without CKD, and evaluate their associations with maternal and fetal outcomes.

Conditions

Chronic Kidney Diseases; Pregnancy; Preeclampsia

Keywords

kidney disease; pregnancy; preeclampsia; kynurenine; maternal outcomes; fetal outcomes

Outcome Measures

Primary Outcomes (1)

• Kynurenine concentration at the 3rd trimester (32±1 weeks) in women with and without CKD

  32±1 weeks

Secondary Outcomes (9)

• Kynurenine concentrations at 1st, 2nd, 3rd trimesters and 2 months postpartum in women with and without CKD

  at 9 months

• preeclampsia

  at 6 months

• gestational hypertension

  at 6 months

• HELLP syndrome

  at 6 months

• postpartum hemorrhage

  at 6 months

Study Arms (2)

Women with chronic kidney disease

OTHER

Other: Blood sampling

Women without chronic kidney disease

OTHER

Other: Blood sampling

Interventions

Blood sampling OTHER

A 14ml blood sample will be collected during the first second and third trimesters of pregnancy and at 2 months (+ 1 month post partum)

Women with chronic kidney disease; Women without chronic kidney disease

Eligibility Criteria

• Age: 18 Years+
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Adult pregnant women \<14 weeks of amenorrhea
• With or without CKD stage 2-4 (eGFR 15-89 mL/min/1.73m², diagnosed before pregnancy)
• Written informed consent
• Affiliation to a social security system

You may not qualify if:

• Multiple pregnancy
• Kidney transplantation
• Persons under guardianship or legal protection

Sponsors & Collaborators

• CHU de Reims: lead

Study Sites (1)

Marie MULLER

Reims, France

Location

MeSH Terms

Conditions

Renal Insufficiency, Chronic; Pre-Eclampsia; Kidney Diseases

Interventions

Blood Specimen Collection

Condition Hierarchy (Ancestors)

Renal Insufficiency; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Hypertension, Pregnancy-Induced; Pregnancy Complications

Intervention Hierarchy (Ancestors)

Specimen Handling; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Punctures; Surgical Procedures, Operative; Investigative Techniques

Central Study Contacts

Vincent DUPONT

CONTACT

03 26 78 76 41; vdupont@chu-reims.fr

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 9, 2026
• First Posted: February 17, 2026
• Study Start: March 1, 2026
• Primary Completion (Estimated): September 1, 2028
• Study Completion (Estimated): May 1, 2029
• Last Updated: February 17, 2026

Record last verified: 2026-01

Locations

FR (1)